Ftse Mib
36.281,22
0,25%
DAX
21.454,82
0,82%
S&P 500
6.044,56
0,54%
NASDAQ
19.584,86
1,26%
Bitcoin
102.275,71
0,19%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Merus NV (MRUS) Merus NV (MRUS) Notizie

Merus NV

MRUS
40,285
-0,115 (-0,28%)
Ultimo aggiornamento: 17:08:31
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
13/1/202502:04GLOBEMerus and Biohaven Announce Collaboration to Co-Develop..
17/12/202403:51EDGAR2Form SCHEDULE 13G - Statement of Beneficial Ownership by..
16/12/202422:01GLOBEMerus announces First Patient Dosed in Phase 2 Trial of..
07/12/202407:30GLOBEMerus’ Petosemtamab Monotherapy Interim Data Continues to..
05/12/202412:03EDGAR2Form 8-K - Current report
04/12/202422:55GLOBEMerus Announces FDA Approval of BIZENGRI®..
02/12/202414:43EDGAR2Form 8-K - Current report
02/12/202414:00GLOBEMerus and Partner Therapeutics Announce License Agreement..
01/12/202417:05GLOBEMerus Announces Publication of an Abstract on Petosemtamab..
05/11/202422:24EDGAR2Form 8-K - Current report
05/11/202412:30GLOBEMerus Receives FDA extension of PDUFA for zenocutuzumab
31/10/202413:08GLOBEMerus Announces Financial Results for the Third Quarter 2024..
31/10/202413:00EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
30/9/202414:00GLOBEMerus Announces First Patient Dosed in LiGeR-HN1, a Phase 3..
17/9/202415:00GLOBEMerus Announces Abstract Accepted for Presentation at the..
22/8/202422:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/8/202414:00GLOBEMerus to Present at Canaccord Genuity’s 44th Annual Growth..
01/8/202422:10GLOBEMerus Announces Financial Results for the Second Quarter..
01/8/202422:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
24/7/202413:00GLOBEMerus Announces First Patient Dosed in LiGeR-HN2, a Phase 3..
08/7/202414:00GLOBEMerus Announces First Patient Dosed in Phase 2 Trial of..
01/7/202414:00GLOBEMerus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical..
17/6/202421:37EDGAR2Form 144 - Report of proposed sale of securities
12/6/202423:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/6/202422:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/6/202420:30GLOBEMerus’ MCLA-129 Demonstrates Promising Single-Agent..
02/6/202418:30GLOBEMerus Presents Interim Data on MCLA-145 Monotherapy and in..
30/5/202423:21EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
30/5/202403:30GLOBEMerus Announces Pricing of Upsized Public Offering of Common..
29/5/202414:00GLOBEMerus to Participate in a Fireside Chat at the Jefferies..
28/5/202422:29EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28/5/202422:06EDGAR2Form 8-K - Current report
28/5/202422:01GLOBEMerus N.V. Announces Proposed Public Offering of Common..
28/5/202413:00GLOBEMerus’ Petosemtamab in Combination with Pembrolizumab..
23/5/202423:00GLOBEMerus Announces Publication of an Abstract on Petosemtamab..
13/5/202414:00GLOBEPetosemtamab granted Breakthrough Therapy Designation by the..
10/5/202422:33EDGAR2Form 8-K/A - Current report: [Amend]
09/5/202422:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/5/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/5/202422:15GLOBEMerus Announces Financial Results for the First Quarter 2024..
08/5/202414:01EDGAR2Form 8-K - Current report
06/5/202422:05GLOBEMerus Announces U.S. FDA Acceptance and Priority Review of..
08/4/202418:00GLOBEMerus Presents Preclinical Data Demonstrating Efficacy of..
03/4/202414:00GLOBEMerus to Participate in a Fireside Chat at the 23rd Annual..
06/3/202414:15EDGAR2Form 8-K - Current report
Apertura: 40,38 Min: 39,645 Max: 40,8199
Chiusura: 40,40

La tua Cronologia

NASDAQ
MRUS
Merus NV
TG
UOF
Urban Outfitters Dl 0001
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network